GENETIC ANALYSIS NK -60

F:8V8 Germany Diagnostics & Research
Market Cap
$2.98 Million
€2.90 Million EUR
Market Cap Rank
#36350 Global
#4436 in Germany
Share Price
€0.04
Change (1 day)
+7.69%
52-Week Range
€0.03 - €0.20
All Time High
€0.98
About

Genetic Analysis AS, a science-based diagnostic company, develops diagnostic solutions for human microbiome market in the United States, Europe, and internationally. It offers GA-map, a platform for the analysis of the human gut microbiota; GA-map Dysbiosis Test that detects and characterizes dysbiosis; and GA-map Analyzer, a cloud-based software solution. The company also provides GA-map Discove… Read more

GENETIC ANALYSIS NK -60 (8V8) - Net Assets

Latest net assets as of : €- EUR

Based on the latest financial reports, GENETIC ANALYSIS NK -60 (8V8) has net assets worth €- EUR as of .

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets €-
% of Total Assets 0%
Annual Growth Rate N/A
5-Year Change N/A
10-Year Change N/A
Growth Volatility N/A

GENETIC ANALYSIS NK -60 - Net Assets Trend (None–None)

This chart illustrates how GENETIC ANALYSIS NK -60's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for GENETIC ANALYSIS NK -60 (None–None)

The table below shows the annual net assets of GENETIC ANALYSIS NK -60 from None to None.

Year Net Assets Change
No yearly data available.

Equity Component Analysis

This analysis shows how different components contribute to GENETIC ANALYSIS NK -60's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • No equity composition insights available.

GENETIC ANALYSIS NK -60 Competitors by Market Cap

The table below lists competitors of GENETIC ANALYSIS NK -60 ranked by their market capitalization.

Equity Growth Attribution

This analysis shows how different factors contributed to changes in GENETIC ANALYSIS NK -60's equity between the two most recent reporting periods.

Insufficient data available to analyze equity growth attribution.

Book Value vs Market Value Analysis

This analysis compares GENETIC ANALYSIS NK -60's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Insufficient data available to analyze book value vs market value.

Capital Efficiency Dashboard

This dashboard shows how efficiently GENETIC ANALYSIS NK -60 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Insufficient data available to analyze capital efficiency metrics.

Industry Comparison

This section compares GENETIC ANALYSIS NK -60's net assets metrics with peer companies in the Diagnostics & Research industry.

Industry Context

  • Industry: Diagnostics & Research
  • Average net assets among peers: $10,792,710,184
  • Average return on equity (ROE) among peers: -33.38%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
GENETIC ANALYSIS NK -60 (8V8) €- N/A N/A $869.15K
Spermosens AB (publ) (9R5) $23.64 Million -27.17% 0.09x $517.28K
BML Inc (BMZ) $81.13 Billion 8.19% 0.43x $462.01 Million
Genomic Vision Société Anonyme (G09) $3.07 Million -162.85% 1.21x $711.54K
ICON Public Limited Company (IJF) $1.85 Billion 17.96% 0.86x $6.43 Billion
Adicon Holdings Limited (K0U) $1.77 Billion 2.65% 1.64x $138.53 Million
WuXi XDC Cayman Inc. (L74) $1.48 Billion 10.52% 0.69x $2.11 Billion
NanoRepro AG (NN6) $57.61 Million 51.59% 0.37x $16.84 Million
PERRIGO (PGO) $24.67 Million -167.93% 0.99x $6.37K